Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Leila Takahashi-Ruiz"'
Autor:
Joseph D. Morris, Leila Takahashi-Ruiz, Lauren N. Persi, Jonathan C. Summers, Erin P. McCauley, Peter Y. W. Chan, Gabriella Amberchan, Itzel Lizama-Chamu, David A. Coppage, Phillip Crews, April L. Risinger, Tyler A. Johnson
Publikováno v:
ACS Omega, Vol 7, Iss 10, Pp 8824-8832 (2022)
Externí odkaz:
https://doaj.org/article/9bb598ea22024299b26fa1e60fc54a64
Autor:
Leila Takahashi-Ruiz, Charles S. Fermaintt, Nancy Wilkinson, Peter Y. Chan, Susan L. Mooberry, April L. Risinger
Publikováno v:
Journal of Clinical and Translational Science, Vol 7, Pp 128-128 (2023)
OBJECTIVES/GOALS: Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks effective targeted treatment options. TNBC's greater degree of immunogenicity than other breast tumors makes immunotherapy a viable strategy. Strategies t
Externí odkaz:
https://doaj.org/article/b311f428910d47a6a3efcf9a48ce57be
Autor:
Leila Takahashi-Ruiz, Charles S. Fermaintt, Nancy J. Wilkinson, Peter Y. W. Chan, Susan L. Mooberry, April L. Risinger
Publikováno v:
Cancers, Vol 14, Iss 23, p 5962 (2022)
Eribulin is a microtubule destabilizer used in the treatment of triple-negative breast cancer (TNBC). Eribulin and other microtubule targeted drugs, such as the taxanes, have shared antimitotic effects, but differ in their mechanism of microtubule di
Externí odkaz:
https://doaj.org/article/2557cc6914cd45a7a980e900f5d28c86
Publikováno v:
Molecules, Vol 27, Iss 13, p 4244 (2022)
Microtubule-stabilizing agents (MSAs) are a class of compounds used in the treatment of triple-negative breast cancer (TNBC), a subtype of breast cancer where chemotherapy remains the standard-of-care for patients. Taxanes like paclitaxel and docetax
Externí odkaz:
https://doaj.org/article/57fba5c4dbac438ab33d49197c1958c1
Autor:
Charles S. Fermaintt, Thilini Peramuna, Shengxin Cai, Leila Takahashi-Ruiz, Jacob Nathaniel Essif, Corena V. Grant, Barry R. O’Keefe, Susan L. Mooberry, Robert H. Cichewicz, April L. Risinger
Publikováno v:
Cancers, Vol 13, Iss 11, p 2834 (2021)
The heterogeneity of triple negative breast cancer (TNBC) has led to efforts to further subtype this disease with the hope of identifying new molecular liabilities and drug targets. Furthermore, the finding that TNBC is the most inherently immunogeni
Externí odkaz:
https://doaj.org/article/4899d7b465ce444ca02682bfdb10108e
Publikováno v:
Cancer Research. 83:P4-07
Triple-negative breast cancer (TNBC) is a heterogenous subtype of breast cancer that lacks effective targeted treatment options. However, TNBC typically has a higher mutational burden and greater degree of immunogenicity than other breast tumors, mak
Autor:
Leila Takahashi-Ruiz, Charles S. Fermaintt, Nancy Wilkinson, Peter Y. Chan, Susan L. Mooberry, April L. Risinger
Publikováno v:
Cancer Research. 83:6397-6397
Triple-negative breast cancer (TNBC) is a heterogenous subtype of breast cancer lacking effective targeted treatment options. However, TNBC typically has a higher mutational burden and greater degree of immunogenicity than other breast tumors, making
Publikováno v:
Molecules; Volume 27; Issue 13; Pages: 4244
Microtubule-stabilizing agents (MSAs) are a class of compounds used in the treatment of triple-negative breast cancer (TNBC), a subtype of breast cancer where chemotherapy remains the standard-of-care for patients. Taxanes like paclitaxel and docetax
Eribulin Enhances Interferon Production by STING Agonists in Models of Triple‐Negative Breast Cancer
Autor:
Leila Takahashi‐Ruiz, Charles S. Fermaintt, Peter Y. Chan, Hui Liang, Susan L. Mooberry, April L. Risinger
Publikováno v:
The FASEB Journal. 36
Autor:
Corena V Grant, Shengxin Cai, Susan L. Mooberry, Thilini Peramuna, Robert H. Cichewicz, Leila Takahashi-Ruiz, Charles S. Fermaintt, Barry R. O'Keefe, April L. Risinger, Jacob Nathaniel Essif
Publikováno v:
Cancers
Volume 13
Issue 11
Cancers, Vol 13, Iss 2834, p 2834 (2021)
Volume 13
Issue 11
Cancers, Vol 13, Iss 2834, p 2834 (2021)
Simple Summary Most breast cancers express the estrogen, progesterone, and/or HER2 receptors and patients are treated with inhibitors targeting these receptors. Triple negative breast cancers (TNBCs) lack these receptors and thus patients with TNBC d